RPTX

Repare Therapeutics Inc

Add to Watchlist

Advanced Chart

1.540

+0.005(0.326%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

1.560

Open

1.540

VWAP

1.54

Vol

41.12K

Mkt Cap

66.16M

Low

1.530

Amount

63.44K

EV/EBITDA(TTM)

Total Shares

42.45M

-43.31M

EV/OCF(TTM)

P/S(TTM)

262.54

Repare Therapeutics Inc. is a clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. The Company utilizes its genome-wide, CRISPR-enabled SNIPRx platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. Its pipeline includes RP-3467, a Phase 1 Polo ATPase inhibitor; RP-1664, a Phase 1 PLK4 inhibitor, and lunresertib, a PKMYT1 inhibitor.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q3

FY2025Q4

FY2026Q1

-0.490

-36.73%

-0.420

-38.04%

0.000

-100%

Estimates Revision

The market is revising Upward the revenue expectations for Repare Therapeutics Inc. (RPTX) for FY2025, with the revenue forecasts being adjusted by 33.33% over the past three months. During the same period, the stock price has changed by 13.24%.

Revenue Estimates for FY2025

Revise Upward

+33.33%

In Past 3 Month

EPS Estimates for FY2025

No Change

0.00%

In Past 3 Month

Stock Price

Go Up

+13.24%

In Past 3 Month

2 Analyst Rating

-2.60% Downside

Wall Street analysts forecast RPTX stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for RPTX is 1.50 USD with a low forecast of 1.50 USD and a high forecast of 1.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

1 Hold

0 Sell

Moderate Buy

-2.60% Downside

Current: 1.540

Low

1.50

Averages

1.50

High

1.50

-2.60% Downside

Current: 1.540

Low

1.50

Averages

1.50

High

1.50

HC Wainwright & Co.

Robert Burns

Strong Buy

Maintains

$10 → $5

2025-03-07

Reason

HC Wainwright & Co.

Robert Burns

Price Target

$10 → $5

2025-03-07

Maintains

Strong Buy

Reason

Stifel

Benjamin Burnett

Strong Buy

Maintains

$9 → $4

2024-12-13

Reason

Stifel

Benjamin Burnett

Price Target

$9 → $4

2024-12-13

Maintains

Strong Buy

Reason

Stifel analyst Benjamin Burnett lowered the firm's price target on Repare Therapeutics to $4 from $9 and keeps a Buy rating on the shares after updated results for camonsertib plus lunresertib came in below expectations. The firm expects the debate after the data to focus on the likelihood of success in endometrial cancer and for continued scrutiny of the balance sheet, the analyst tells investors.

LifeSci Capital

Charles Zhu

Buy

Hold

Downgrades

n/a

2024-12-13

Reason

LifeSci Capital

Charles Zhu

Price Target

n/a

2024-12-13

Downgrades

Buy

Hold

Reason

LifeSci Capital downgraded Repare Therapeutics to Market Perform from Outperform.

HC Wainwright & Co.

Robert Burns

Strong Buy

Reiterates

$10

2024-11-08

Reason

HC Wainwright & Co.

Robert Burns

Price Target

$10

2024-11-08

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Robert Burns

Strong Buy

Reiterates

$10

2024-10-24

Reason

HC Wainwright & Co.

Robert Burns

Price Target

$10

2024-10-24

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Robert Burns

Strong Buy

Reiterates

$10

2024-09-23

Reason

HC Wainwright & Co.

Robert Burns

Price Target

$10

2024-09-23

Reiterates

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Repare Therapeutics Inc (RPTX.O) is 0.00, compared to its 5-year average forward P/E of -6.44. For a more detailed relative valuation and DCF analysis to assess Repare Therapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-6.44

Current PE

0.00

Overvalued PE

-0.28

Undervalued PE

-12.60

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-3.37

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.84

Undervalued EV/EBITDA

-7.58

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

93.09

Current PS

3.30

Overvalued PS

237.09

Undervalued PS

-50.90

Financials

Annual

Quarterly

FY2025Q2

YoY :

-76.70%

250.00K

Total Revenue

FY2025Q2

YoY :

-46.24%

-20.06M

Operating Profit

FY2025Q2

YoY :

-51.85%

-16.74M

Net Income after Tax

FY2025Q2

YoY :

-52.44%

-0.39

EPS - Diluted

FY2025Q2

YoY :

-46.44%

-16.34M

Free Cash Flow

FY2025Q2

YoY :

0.00%

100.00

Gross Profit Margin - %

FY2025Q2

YoY :

+35383.90%

-41.34K

FCF Margin - %

FY2025Q2

YoY :

+106.66%

-6.70K

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

42.5K

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

31.7K

Volume

6-9

Months

26.5K

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

0.0

Volume

Months

6-9

0.0

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

42.5K

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

RPTX News & Events

Events Timeline

2025-08-08 (ET)

2025-08-08

07:35:48

Repare Therapeutics reports Q2 EPS (39c) vs. (82c) last year

2025-07-15 (ET)

2025-07-15

16:06:28

Repare Therapeutics enters licensing pact with Debiopharm for Lunresertib

2025-05-13 (ET)

2025-05-13

16:07:50

Repare Therapeutics expects cash to fund operations through 2027

News

2.0

07-16Benzinga

Why Data Storage Shares Are Trading Higher By 35%; Here Are 20 Stocks Moving Premarket

8.5

05-01Newsfilter

Newly Launched DCx Biotherapeutics In-Licenses Discovery Platforms and Retains Talent and Infrastructure From Repare Therapeutics to Accelerate Development of Multi-Modal Antibody Drug Conjugates

5.0

04-12Benzinga

Cathie Wood's Ark Invest Offloads Uipath, Prime Medicine, And Repare Therapeutics